Europska Unija - hrvatski - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - cjepiva - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, sheep, inactivated viral vaccines - ovca - aktivna imunizacija ovaca od 1. 5 mjeseci starosti kako bi se spriječila viremija uzrokovana virusom bolesti plavog jezika, serotipovima 1 i 8. početak imuniteta: 21 dan nakon završetka primarne sheme cijepljenja. trajanje imuniteta: 12 mjeseci.

Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium sa  - inactivated feline rhinotracheitis virus, inactivated feline calicivirus, inactivated feline chlamydophila felis, inactivated feline leukaemia virus, inactivated feline panleukopenia virus - immunologicals - mačke - za aktivna imunizacija zdravih mačaka devet tjedana i stariji protiv панлейкопении i virus mačje leukemije i protiv respiratornih bolesti uzrokovane virusom ринотрахеита mačke, mačka калицивирус i klamidija feliz.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra s.a. - inactivated bordetella bronchiseptica, strain 833cer, recombinant type-d pasteurella-multocida toxin - immunologicals - svinje (nazimice i krmače) - za pasivne zaštite поросятам kroz kolostrum nakon aktivne imunizacije krmača i popravak svinje za smanjenje kliničkih znakova i poraza progresivni i непрогрессивный атрофическом рините, ali i da se smanji gubitak težine povezan s Бордетеллы-bronchiseptica i pasteurella-multocida infekcije u razdoblju tova. zadatak istraživanja su pokazala da je pasivni imunitet kod prasadi traje do šest tjedana, dok u kliničkim terenska ispitivanja, blagotvoran utjecaj cijepljenja (smanjenje nosa poraza i rezultat gubitka težine) uočeni do klanja.

Hrvatska - hrvatski - Ecolab

ecolab deutschland gmbh -

Europska Unija - hrvatski - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split virusa influence, inaktiviran, koji sadrži antigen: a / vietnam / 1194/2004 (h5n1) kao soj koji se koristio (nibrg-14) - influenza, human; immunization; disease outbreaks - cjepiva - profilakcija gripe u službeno prijavljenoj pandemijskoj situaciji. cjepivo protiv influence pandemije treba koristiti u skladu s službenim smjernicama.

Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - Инактивированные virusnih i инактивированные bakterijska cjepiva - svinje - za aktivne imunizacije svinja s 3 tjedna starosti protiv svinjske цирковирус tipa 2 (pcv2) za smanjenje količine virusa u krvi i лимфоидных tkiva i fekalne prolijevanja, uzrokovane infekcijom s ЦВС2. za aktivnu imunizaciju svinja u dobi od 3 tjedna protiv mycoplasma hyopneumoniae za smanjenje plućnih lezija uzrokovanih infekcijom s m. hyopneumoniae.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - antigeni virusa influence (hemaglutinin i neuraminidaza) soja a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - cjepiva - aktivna imunizacija protiv h5n1 podtipa virusa gripe a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinje - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - imunološke za suidae - svinje - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.